生物标志物指导下的非小细胞肺癌靶向治疗

生物标志物指导下的非小细胞肺癌靶向治疗

作者：段建春， 王洁， DUAN Jian-chun， WANG Jie

作者单位：北京肿瘤医院胸部肿瘤内科,北京大学临床肿瘤学院,100142

刊名：

肿瘤研究与临床

英文刊名：CANCER RESEARCH AND CLINIC

年，卷(期)：2010,22(9)

参考文献(17条)

1.Kobayash K Randomized study on Japanese population with EGFR mutation 2009

2.Rosell R;Moran T;Queralt C Screening for epidermal growth factor receptor mutation in lung cancer [外文期刊] 2009(10)

3.Pirker R;Pereira JR;Szczesna A Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX):an open-label randomised phase Ⅲ trial 2009

4.Mok TS;WU YL;Thongpraser S Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma 2009

5.Zhang W;Jiang Y;Zhang Predictive values of intratumoral microvascular density (MVD) in the

patients (pts) with advanced NSCLC and metastatic colorectal cancer (mCRC) receiving chemotherapy plus bevacizumab 2009

6.Shaked Y;Bocci G;Munoz R Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose[外文期刊] 2005(7)

7.Phase Ⅲmulticenter,international clinical trial:Erlntinib Versus placebo as maintenance therapy in advanced non-small cell lung cancer finished first-line chemotherapy 2009

8.Paz-Ares LG;Altug S;Vaury AT Treatment rationale and study design for a phase Ⅲ,double-

blind,placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced non-squamous non-small cell lung cancer[外文期刊] 2010

9.Douillard JY;Kim E;Hirsh V Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-smallcell lung cancer pre-treated with platinum-based chemotherapy:A

randomized,open-label phase Ⅲ study (INTEREST) 2007(suppl 4)

10.Shepherd F;Pereir JR;Giuleonu T Erlotinib in previously treated non-small cell lung cancer[外文期刊] 2005(2)

11.Butts CA;Bodkin D;Middleman EL Randomized phase Ⅱ study of gemcitabine plus cisplatin or carboplatin[corrected],with or without cetuximab,as first-line therapy for patients with advanced or metastatic non small-cell lung cancer 2007

12.Rosell R;Robinet G;Szczesna A Randomized phase Ⅱ study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer[外文期刊] 2008(2)

13.Dowlati A;Robert G;Alan B Cell adhesion molecules,vascular endothelial growth factor,and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an eastern cooperative oncology group study[外文期刊] 2008(5)

Mobilization:Implications for Antiangiogenic Drugs as Chemosensitizing Agents[外文期刊] 2008(3) 15.Jurado J;Ortega JA;Iglesias J Vascular endothelial growth factor receptor-2 (VEGFr-2) genetic polymorphisma as predictors to antiangiogenic therapy 2009

16.Hanrahan EO;Lin HY;Du DZ Correlative analyses of plasma cytokine/angiogenic factor (C/AF) profile,gender and outcome in a randomized,three-arm,phase Ⅱ trial of first-line vandetanib (VAN) and/or carboplatin plus paclitaxel (CP) for advanced non-small cell lung cancer (NSCLC) 2007

17.Zhang W;S.E.Dahlberg;D.Yang Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel:Subset pharmacogenetic analysis of ECOG 4599 2009

本文链接：https://www.wendangku.net/doc/0b4114894.html,/Periodical_zlyjylc201009004.aspx